Ciprofloxacin

C. diff Risk

High

Oral Bioavailability

Excellent

Dosing

PO: 500-750mg po q12h

IV: 400mg IV q8-12h

eGFR 0 - 10eGFR 10 - 50eGFR > 50400mg IV q24h

500mg PO q24h400mg IV q24h

250-500mg PO q12h400mg IV q8-12h

500-750mg PO q12h

400mg IV or 500mg PO q24h

Dose after HD on dialysis days

400mg IV q12h

General Information

Adverse Effects

  • QTc prolongation

  • Dysglycemia

  • Rash

  • Tendinopathy and rupture

  • GI upset

  • Weakness exacerbation in myasthenia gravis

  • CNS toxicity including confusion, psychosis.

Common Usage

Pseudomonal and other gram negative infections of urinary tract, bone/joint, abdomen and other sites.

Drug Monitoring

Monitor QTc in patients with increased risk.

Major Interactions

  • Other QTc prolonging agents

  • Divalent cations - Decreased absorption

  • NSAIDs - Increase seizure risk

  • Warfarin - Increased INR

Pharmacology

Antimicrobial class: Fluoroquinolone

Pregnancy category: C

Average serum half life: 4 hours

Biliary penetration: Therapeutic

CSF penetration: Moderate

Lung penetration: Therapeutic

Urine penetration: Therapeutic